Interesting ArticleInteresting article, particularly the part below:
"But getting to market alone would be no small feat. In fact,
BioWorld Insightrecently reported that only one private firm in five years had beenable to pull that off. Cambridge, Mass.-based GloucesterPharmaceuticals Inc. made it all the way through approval with Istodax(romidepsin) for cutaneous T-cell lymphoma with about $100 million inventure money.
Shortly after Istodax cleared the FDA, Gloucester was snatched up by Summit, N.J.-based Celgene Corp. for $640 million. (See BioWorld Today, Dec. 8, 2009.)"
https://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=53491